The role and efficacy of Rucaparib

Rucaparib (Rucaparib) is an oral, small-molecule poly(ADP-ribose) polymerase inhibitor indicated for the treatment of patients with recurrent ovarian cancer in the maintenance and treatment settings and metastatic castration-resistant prostate cancer associated with deleterious BRCA1 or BRCA2 mutations. Rucaparib had a manageable safety profile; the most common adverse events in both indications were fatigue and nausea.

Accumulation of plasma exposure occurred following repeated administration of the approved 600 mg twice daily dose. Steady state was achieved after one week of continuous twice daily dosing. Rucaparib has moderate oral bioavailability and can be administered with or without food. Although the high-fat meal weakly increased maximum concentration and area under the curve, this effect was not clinically significant. Mass balance analysis showed that within 12 days, rucaparib dose was almost completely restored, with metabolism, renal and hepatic excretion as the elimination pathways. Population pharmacokinetic analysis of rucaparib showed no effect of age, sex, race, or body weight.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).